Eiger BioPharmaceuticals Inc. | Mutual Funds
Mutual Funds that own Eiger BioPharmaceuticals Inc.
Prudential Jennison Health Sciences Fund
620,739
4.37%
0
0.31%
07/31/2018
HBM BioVentures Ltd.
580,000
4.08%
0
0.51%
12/31/2017
Vanguard Total Stock Market Index Fund
294,747
2.06%
20,500
0%
07/31/2018
Vanguard Extended Market Index Fund
125,834
0.89%
0
0%
07/31/2018
Fidelity Spartan Extended Market Index Fund
53,165
0.37%
0
0%
07/31/2018
Bridgeway Ultra Small Company Market Fund
50,000
0.35%
0
0.15%
12/31/2017
Eventide Healthcare & Life Sciences Fund
36,000
0.25%
-27,000
0.07%
06/29/2018
FCP OP Medical BioHe@lth-Trends
32,237
0.23%
0
0.24%
11/30/2017
APO Medical Opportunities
23,080
0.16%
0
0.06%
03/31/2018
Inver-99, SICAV
22,973
0.16%
11,971
7.33%
03/31/2018
| Address |
2155 Park Boulevard
Palo Alto California 94306
United States
|
|
Employees
|
- |
| Website |
http://www.eigerbio.com |
| Updated |
07/08/2019 |
| Eiger BioPharmaceuticals, Inc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for orphan diseases. It focuses on product candidates for the treatment of orphan diseases such as Sarasar, Pegylated Interferon Lambda, Exendin 9-39, and Ubenimex. The company was founded by David A. |
